Summary of Product Characteristics

1. Name of the Medicinal Product
Brand Name:
COSVATE – GM CREAM
Generic Name: Clobetasol Propionate and Gentamicin Cream

2. Qualitative and Quantitative Composition
Each gram of cream contains:
Clobetasol Propionate.....0.05% w/w
Miconazole Nitrate.....2% w/w
Gentamicin Sulphate.....0.1% w/w

For the full list of excipients, see section 6.1.

3. Pharmaceutical form
Cream for topical administration.

4. Clinical particulars

4.1 Therapeutic indications:

COSVATE GM Cream is a super-high potency corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in which secondary bacterial infection is present, suspected or likely to occur. Treatment beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis.

4.2 Posology and method of administration
Posology

Apply a thin layer of COSVATE GM Cream to the affected skin areas twice daily and rub it gently and completely. Treatment should be limited to 2 consecutive weeks and amounts greater than 50 g/week should not be used. COSVATE GM Cream should not be used with occlusive dressings.

Creams are especially appropriate for moist or weeping surfaces.

Adults, Elderly and Children over 1 year

Apply thinly and gently rub in using only enough to cover the entire affected area once or twice a day until improvement occurs (in the more responsive conditions this may be within a few days), then reduce the frequency of application or change the treatment to a less potent preparation. Allow

adequate time for absorption after each application before applying an emollient.

Repeated short courses of clobetasol propionate may be used to control exacerbations.

In more resistant lesions, especially where there is hyperkeratosis, the effect of clobetasol can be enhanced, if necessary, by occluding the treatment area with polythene film. Overnight occlusion only is usually adequate to bring about a satisfactory response. Thereafter improvement can usually be maintained by application without occlusion.

If the condition worsens or does not improve within 2-4 weeks, treatment and diagnosis should be re-evaluated.

Treatment should not be continued for more than 4 weeks. If continuous treatment is necessary, a less potent preparation should be used.

The maximum weekly dose should not exceed 50 gms/week.

Therapy with clobetasol should be gradually discontinued once control is achieved and an emollient continued as maintenance therapy.

Rebound of pre-existing dermatoses can occur with abrupt discontinuation of clobetasol.

Recalcitrant dermatoses: Patients who frequently relapse

Once an acute episode has been treated effectively with a continuous course of topical corticosteroid, intermittent dosing (once daily, twice weekly, without occlusion) may be considered. This has been shown to be helpful in reducing the frequency of relapse.

Application should be continued to all previously affected sites or to known sites of potential relapse. This regimen should be combined with routine daily use of emollients. The condition and the benefits and risks of continued treatment must be re-evaluated on a regular basis.

Paediatric population

Cosvate GM Cream is contraindicated in children under one year of age.

Children are more likely to develop local and systemic side effects of topical corticosteroids and, in general, require shorter courses and less potent agents than adults.

Care should be taken when using clobetasol propionate to ensure the amount applied is the minimum that provides therapeutic benefit.

Duration of treatment for children and infants

Courses should be limited if possible to five days and reviewed weekly. Occlusion should not be used.

Application to the face

Courses should be limited to five days if possible and occlusion should not be used.

Elderly

Clinical studies have not identified differences in responses between the elderly and younger patients. The greater frequency of decreased hepatic or renal function in the elderly may delay elimination if systemic absorption occurs. Therefore the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit.

Renal / Hepatic Impairment

In case of systemic absorption (when application is over a large surface area for a prolonged period) metabolism and elimination may be delayed therefore increasing the risk of systemic toxicity. Therefore the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit.

Method of administration

Cutaneous use. For external use only.

Method of administration

Cutaneous use. For external use only.

4.3 Contraindications

COSVATE GM Cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations. Special warnings and precautions for use

4.4. Special Warnings and Precautions:

General: COSVATE GM Cream should not be used in the treatment of rosacea or perioral dermatitis, and should not be used on the face, groin, or axillae. Systemic absorption of topical corticosteroids can produce reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal from treatment. Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Paediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios.

Information for Patients: Patients using topical corticosteroids should receive the following information and instructions:

1. This medication is to be used as directed by the Physician. It is for external use only. Avoid contact with the eyes.
2. This medication should not be used for any disorder other than that for which it was prescribed.

3. The treated skin area should not be bandaged, otherwise covered, or wrapped so as to be occlusive unless directed by the Physician.
4. Patients should report any signs of local adverse reactions to the Physician. **Pregnancy:** Pregnancy Category C. COSVATE GM Cream should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
Paediatric Use: Use in Paediatric patients under 12 years of age is not recommended.
Nursing Mothers: It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Nevertheless, a decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother.

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed. Interactions with systemically administered medicinal products are considered minimal.

4.6. Fertility, pregnancy and lactation Pregnancy

Pregnancy: Pregnancy Category C. COSVATE GM Cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nursing Mothers: It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Nevertheless, a decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother.

4.7 Effects on ability to drive and use machines

COSVATE GM cream has no or negligible influence on the ability to drive or to use machines.

4.8 Undesirable effects

The estimation of the frequency of undesirable effects is based on a pooled analysis of data from clinical studies and spontaneous reporting.
The most frequently reported adverse reaction during treatment is pruritus. Undesirable effects are listed by MedDRA SOC and the individual undesirable effects are listed starting with the most frequently reported. Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Very common ≥1/10
Common ≥1/100 and
<1/10
Uncommon ≥1/1,000 and

<1/100 Rare ≥1/10,000
and <1/1,000 Very
rare
<1/10,000
Not known (cannot be estimated from the available data)

Immune system disorders	
Uncommon: (≥1/1,000 and <1/100)	Hypersensitivity
Eye disorder	
Not known	Vision, blurred*
Skin and subcutaneous tissue disorders	
Uncommon: (≥1/1,000 and <1/100)	Dermatitis contact Eczema (condition aggravated) Skin burning sensation Pruritus Dry skin
Rare: (≥1/10,000 and <1/1,000)	Erythe ma Urticari a Rash (including rash erythematous and rash generalised)
General disorders and administration site conditions	
Uncommon: (≥1/1,000 and <1/100)	Application site pain Application site irritation
Rare: (≥1/10,000 and <1/1,000)	Application site swelling Application site vesicles

*See also section 4.4
Systemic undesirable class effects of corticosteroids like betamethasone valerate include adrenal suppression especially during prolonged topical administration (see section 4.4).

Raised intra-ocular pressure, glaucoma or cataract may also occur after topical use of corticosteroids near the eyes, particularly with prolonged use and in patients predisposed to developing glaucoma and cataract (see section 4.4).
Dermatological undesirable class effects of potent corticosteroids include: Atrophy, dermatitis (including dermatitis contact and dermatitis acneiform), perioral dermatitis, skin striae, telangiectasia, rosacea, erythema, hypertrichosis, hyperhidrosis and depigmentation. Ecchymosis may also occur with prolonged use of topical corticosteroids.
Class effects for corticosteroids have been uncommonly reported for Futop B cream as described in the frequency table above.

Paediatric population
The observed safety profile is similar in children and adults (see section 4.4).

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via pharmacy and poisons board, Pharmacovigilance Electronic Reporting System (PvERS) https://pv.pharmacyboardkenya.org

4.4 OVERDOSAGE:
Topically applied COSVATE GM Cream can be absorbed in sufficient amounts and does not produce systemic effects

5 Pharmacological properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: D07CC01, corticosteroids
(Group III) and antibiotics in combination, for external use.
ATC code: D07CC01.
Futop B cream combines the well-known anti-inflammatory and antipruritic effects of betamethasone with the potent topical antibacterial action of fusidic acid. Betamethasone valerate is a topical steroid rapidly effective in those inflammatory dermatoses which normally respond to this form of therapy. More refractory conditions can often be treated successfully. When applied topically, fusidic acid is effective against Staphylococcus aureus, Streptococci, Corynebacteria, Neisseria and certain Clostridia and Bacteroides. Concentrations of 0.03 to 0.12 microgram per ml inhibit nearly all strains of S. aureus. The antibacterial activity of fusidic acid is not diminished in the presence of betamethasone.

Mechanism of Action:

Clobetasol Propionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
Gentamicin is an aminoglycoside antibiotic indicated in the treatment of gram-positive as well as gram-negative infections.

Gentamicin is effective against most gram-negative

organisms including *E coli, Klebsiella pneumoniae, Enterobacter aerogenes, Serratia marcescens* and *Citrobacter freundii*.

5.2 Pharmacokinetic properties

There are no data which define the pharmacokinetics of Futop B cream, following topical administration in man.
However, *in vitro* studies show that fusidic acid can penetrate intact human skin. The degree of penetration depends on factors such as the duration of exposure to fusidic acid and the condition of the skin. Fusidic acid is excreted mainly in the bile with little excreted in the urine.
Betamethasone is absorbed following topical administration. The degree of absorption is dependent on various factors including skin condition and site of application. Betamethasone is metabolised largely in the liver but also to a limited extent in the kidneys, and the inactive metabolites are excreted with the urine

5.3 Preclinical Safety data:

Studies of corticosteroids in animals have shown reproductive toxicity (e.g., cleft palate, skeletal malformations, low birth weight).

6 Pharmaceutical particulars:

6.1 List of Excipients

Disodium EDTA, Propylene Glycol, White soft Paraffin, Cetostearyl Alcohol, Cetomacrogol–1000, Liquid Paraffin (Light), Chlorocresol, Dibasic potassium Phosphate & Purified water.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

24 months

6.4 **Special precautions for storage** Store below 30°C in a dry and dark place. DO NOT FREEZE.

6.5 Nature and contents of container

The cream is filled in printed laminated tubes with internal lacquer coating and HDPE screw-on caps and enclosed in an outer carton along with pack insert.

Pack sizes available are 5 g and 15 g. Not all pack

sizes may be marketed.

6.6 Special precautions for disposal and other handling
No Special requirements.

7.0 Marketing Authorization Holder Eris Oaknet Healthcare Pvt. Ltd. 3rd Floor, A Wing, Shilp Accord, Opp. Time Square II, Thaltej, Ahmedabad – 380054, Gujarat, India.

Manufactured by:
Curetech Skincare
At: Plot No. 33 & 34, Phase-IV, Bhatoli Kalan, Baddi, Distt Solan, Himachal Pradesh – 173 205, India.

8./0 Marketing Authorization Numbers
H2006/302

9.0 Date of first authorization/renewal of the authorization
Date of First Authorization: 08/10/2018

10.0 Date of revision of the text
11/08/2026